Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)

Overview

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a public-private partnership led by the National Institutes of Health (NIH) and coordinated by the Foundation for the National Institutes of Health (FNIH) to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and treatments.

ACTIV brings together NIH with its sibling agencies in the Department of Health and Human Services, including the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA); other government agencies, including the Department of Defense (DOD) and Department of Veterans Affairs (VA); the European Medicines Agency (EMA); and representatives from academia, philanthropic organizations and biopharmaceutical companies.

The COVID-19 pandemic is an unprecedented global crisis that has been met with a swift and extraordinary response. The research community is sifting through more than 100 potential preventives and treatments. However, because so many studies are recruiting patients, many of those studies could fail to enroll enough participants to answer their research questions. In addition, lack of coordination could make interpretation and comparison of the results difficult.

With limited resources, there is a need to coordinate and streamline processes to make the best use of biomedical research resources and testing of preclinical compounds. Also, there is a need to prioritize the most promising vaccine candidates and move them into clinical trials in a way that is safe and efficient.

For more information or to view Executive Committee and Working Group members, please visit the NIH website.

Goals:

The goals of ACTIV are to:

  • Develop a collaborative, streamlined forum to identify preclinical treatments
  • Accelerate clinical testing of the most promising vaccines and treatments
  • Improve clinical trial capacity and effectiveness
  • Accelerate the evaluation of vaccine candidates to enable rapid authorization or approval

Clinical Trial Protocols

Leadership Organizations

Government

  • Biomedical Advanced Research and Development Authority
  • Centers for Disease Control and Prevention
  • Department of Defense
  • Department of Veterans Affairs
  • European Medicines Agency
  • National Institutes of Health
  • U.S. Food and Drug Administration

Not-for-Profit

  • Bill & Melinda Gates Foundation
  • Fred Hutchinson Cancer Research Center
  • Foundation for the National Institutes of Health
  • RTI International

Industry

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bristol Myers Squibb
  • Eisai
  • Eli Lilly and Company
  • Evotec
  • Gilead
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna
  • Novartis
  • Novavax
  • Pfizer
  • Roche-Genentech
  • Rhythm Therapeutics
  • Sanofi
  • Takeda
  • Vir Biotechnology

FNIH Contact

Publications

Resources

Media

Submit Ideas to ACTIV